Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
47.91
+0.48 (1.01%)
At close: Dec 5, 2025, 4:00 PM EST
48.43
+0.52 (1.09%)
After-hours: Dec 5, 2025, 6:53 PM EST
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Collegium Pharmaceutical stock have an average target of 45.4, with a low estimate of 37 and a high estimate of 50. The average target predicts a decrease of -5.24% from the current stock price of 47.91.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $45 → $48 | Strong Buy | Maintains | $45 → $48 | +0.19% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $44 → $46 | Strong Buy | Maintains | $44 → $46 | -3.99% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | -3.99% | Oct 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | -8.16% | Aug 11, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $36 → $37 | Hold | Reiterates | $36 → $37 | -22.77% | May 9, 2025 |
Financial Forecast
Revenue This Year
797.84M
from 631.45M
Increased by 26.35%
Revenue Next Year
827.14M
from 797.84M
Increased by 3.67%
EPS This Year
7.70
from 1.86
Increased by 314.97%
EPS Next Year
8.23
from 7.70
Increased by 6.85%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 824.0M | 868.4M | ||||
| Avg | 797.8M | 827.1M | ||||
| Low | 763.8M | 761.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 30.5% | 8.8% | ||||
| Avg | 26.4% | 3.7% | ||||
| Low | 21.0% | -4.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 7.98 | 10.59 | ||||
| Avg | 7.70 | 8.23 | ||||
| Low | 7.36 | 6.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 329.8% | 37.4% | ||||
| Avg | 315.0% | 6.9% | ||||
| Low | 296.4% | -10.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.